Dual Trigger, Urinary HCG or Recombinant HCG, Which is the Best !?

Dual Trigger, Urinary HCG or Recombinant HCG, Which is the Best !? a Prospective Randomized Controlled Comparative Study

a comparative study among dual trigger, urinary HCG and recombinant HCG regarding the outcome of ICSI- antagonist cycles

Study Overview

• Status: Recruiting
• Conditions: IVF

Detailed Description

a comparative study among dual trigger, urinary HCG and recombinant HCG regarding the outcome (oocyte quality, fertilization rate, implantation rate, clinical pregnancy rate as well as the incidence of OHSS) in ICSI- antagonist cycles

• Study Type: Observational
• Enrollment (Anticipated): 600

Contacts and Locations

• Study Contact: Name: Kamal eldin Rageh, M.D.; Phone Number: 0097333153871; Email: dr_kamal_rageh@yahoo.com
• Study Contact Backup: Name: Ahmed Barakat, FRCOG; Phone Number: 0097317727888; Email: ahmed.barakat@yahoo.com

Study Locations

• Bahrain
  • Adliya
    • Manama, Adliya, Bahrain, 15006
      • Recruiting
      • Al-BARAKA FERTILITY HOSPITAL
      • Contact: AHMED BARAKAT, FRCOG; Phone Number: 0097336660500; Email: ahmed_barakat@yahoo.com
      • Contact: Kamal Rageh, M.D; Phone Number: 0097333153871; Email: dr_kamal_rageh@yahoo.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 36 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

• Sampling Method: Probability Sample

Study Population

patients <40 years of age who underwent IVF/ICSI cycles using a GnRH antagonist protocol, then at the time of triggering, we divided the patients to 3 groups by for triggering by a dual trigger, urinary HCG and recombinant HCG and then will check the outcome regarding the maturity and oocyte quality, implantation rate, clinical pregnancy rate as well as incidence of OHSS

Description

Inclusion Criteria:

• patients <40 years of age who underwent IVF/ICSI cycles using a GnRH antagonist protocol

Exclusion Criteria:

• age: > 40 years
• BMI > 30 ,
• long agonist protocol
• were chromosomal and genetic disorders, abnormal ultrasonogram of the uterine cavity

Study Plan

How is the study designed?

Design Details

• Observational Models: Other
• Time Perspectives: Prospective

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort
DUAL TRIGGERING; PATIENTS WILL RECEIVE DUAL TRIGGERING
URINARY HCG; PATIENTS WILL RECEIVE URINARY HCG
RECOMBINANT HCG; PATIENTS WILL RECEIVE RECOMBINANT HCG

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
clinical pregnancy rate,	4 WEEKS
implantation rate,	2 WEEKS
incidence of OHSS.	1 WEEK

Collaborators and Investigators

• Sponsor: Al Baraka Fertility Hospital

Study record dates

Study Major Dates

• Study Start (Actual): February 9, 2020
• Primary Completion (Anticipated): November 30, 2021
• Study Completion (Anticipated): December 1, 2021

Study Registration Dates

• First Submitted: February 9, 2020
• First Submitted That Met QC Criteria: February 9, 2020
• First Posted (Actual): February 11, 2020

Study Record Updates

• Last Update Posted (Actual): September 28, 2021
• Last Update Submitted That Met QC Criteria: September 27, 2021
• Last Verified: September 1, 2021

More Information

Terms related to this study

• Keywords: OHSS; HCG; Dual trigger implantation,; ANTAGONIST
• Other Study ID Numbers: AlBarakaBH-KAMAL

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No